Precision mass spec imaging based structure-function signatures of diabetic glomerulopathy
Ended Project Grant Awarded Last action
- Award ID
- R43DK130732
- Recipient
-
Sygnamap Inc. UEI FH41QG5NZ2Y6
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $919,500
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Funding
-
- $619,500.00 Federal
- $300,000.00 Non-federal
- Place of performance
- San Antonio, TX 78229, USA
Award details come from USAspending.gov.
Description
- Abstract
- There are currently >450,000 patients on dialysis and ~120,000 patients will have to begin dialysis each year in the united states. Along with a marked reduction in quality of patient life, the cost to the US medicare system is in excess of $114B per year. Therefore, there is an urgent need for developing new platforms that will enhance the drug development process for new therapies to reduce the rate of progression to end-stage kidney disease. Non-invasive biomarkers may be useful but do not directly identify the pathways linked to pathology in the kidney. An approach that integrates tissue structure with functional readouts in a kidney biopsy would be a major advance. We are developing a computational platform that leverages mass spec imaging data coupled with computational pathology for kidney tissue as a technology that will address this unmet need. With our computational platform we can identify signatures linked to normal and abnormal pathology on the same tissue section. This is a powerful approach to understand kidney pathology and will be of great value for drug development for kidney disease. Parameters related to reproducibility across pre-clinical models of diabetic kidney disease interpretation will be optimized during phase I. Upon completion of the sbir phase I project we will have rigorous data to determine consistency of diseased glomerular signatures in diabetic nephropathy. This proof of concept data will make IT attractive to pharma and biotech to adopt this platform for application for their therapeutic programs for diabetic kidney disease.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $6,500 | $0 | |
| Amendment | $6,500 | $0 | |
| Amendment | $6,500 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $300,000 | $0 | |
| Original award | $300,000 | $300,000 |
Show all 11
Quick answers
Who received award R43DK130732?
R43DK130732 was awarded to Sygnamap Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 8, 2021.
How much is award R43DK130732 worth?
$919,500 has been obligated on R43DK130732: $619,500 in federal funding and $300,000 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award